



For release: 19 May 2009

Xention Limited Strengthens Team with New Director of Business Development

CAMBRIDGE, UK - XENTION LTD, the Cambridge-based biopharmaceutical company specialising in the discovery and development of ion channel-modulating drugs, announced today the appointment of Dr Calum Graham as Director of Business Development.

Dr Graham is an experienced business development executive with a strong scientific background and expert knowledge of the drug development process gained over nineteen years in the pharmaceutical industry. He joins Xention from GlaxoSmithKline, where he held the position of Director of Scientific Licensing in Worldwide Business Development for the last six years.

While at GSK, Dr Graham was responsible for business development and licensing within the neurosciences therapeutic area, one of GSK's largest franchises. He led the evaluation of numerous licensing and acquisition opportunities, including completion of over twenty-five due diligences and the successful completion of numerous, substantial deals. Prior to this, he held senior roles in a number of other departments within GSK including Head of Disease Strategy in the Neurology & GI Centre of Excellence for Drug Discovery (CEDD) and Assistant Director in the Anti-Infective Therapeutic Unit. He holds a PhD in Pharmacology from the University of Dundee.

"We are delighted that Calum has joined us in this newly created role" commented Tim Brears, Xention's chief executive. "His many years of experience in pharmaceutical drug development will be invaluable as the interest in our programmes from third parties increases. We look forward to working more closely with him through the next phase of the company's development".



For further information, please contact:

Tim Brears
CEO
Xention Limited

+44 (0)1223 493 900

Anna Dunphy
De Facto Communications

+44 (0)20 7861 3838

Notes to Editors:

Xention Ltd is a leader in the discovery and development of ion channel-modulating drugs. The Company's potential breakthrough drugs in clinical development include XEN-D0101, a new atrial selective potassium channel blocker for atrial fibrillation, and XEN-D0501, a novel ion channel modulator for the treatment of overactive bladder. Xention also has preclinical research programmes in atrial fibrillation, pain and autoimmune disease. The Company uses proprietary ion channel expertise and technologies to accelerate the discovery of potent and selective ion channel drugs. In particular, Xention is a leader in the use of true electrophysiological data, ion channel chemoinformatics and experienced medicinal chemistry to identify potent new small molecule drugs in this rapidly evolving field of medicine. For further information, please see their website <http://www.xention.com>.

Xention Limited, Iconix Park
London Road, Pampisford
Cambridge CB22 3EG

Tel: +44 (0)1223 493900
Fax: +44 (0)1223 493901
www.xention.com